CD8A and melanoma: Here we found that K2-Fc, an antibody derivative that blocks the PD-1:PD-L1 axis and enables enhanced ADCC, could augment IL-15/IL-15Rα-mediated melanoma cell killing and could synergistically improve CD8+ T cell and NK cell activation.